Plexium

Plexium's DELTA Discovery™ platform enables rational design and discovery of monovalent targeted protein degraders and molecular glues, expanding the druggable target space and advancing novel precision medicines into clinical development.

The company has advanced multiple clinical-stage protein degraders through its platform and has a pipeline of potential first-in-class and best-in-class therapeutic candidates. It is backed by investors including The Column Group, TCG X, Pivotal Bioventure Partners, BVF Partners, DCVC Bio, aMoon, and Lux Capital.